Literature DB >> 16126281

Subcutaneous interferon-beta injections in patients with multiple sclerosis initiate inflammatory skin reactions by local chemokine induction.

Mathias Buttmann1, Matthias Goebeler, Atiye Toksoy, Sybille Schmid, Wolfgang Graf, Friederike Berberich-Siebelt, Peter Rieckmann.   

Abstract

Subcutaneous Interferon-beta (IFN-beta) injections for the treatment of multiple sclerosis (MS) frequently cause inflammatory injection site reactions. To study the role of chemokines we obtained skin biopsies from 7 MS patients 24 h after injection. At the IFN-beta but not at the contralateral placebo injection sites, we observed strong IP-10/CXCL10 and moderate MCP-1/CCL2 expression associated with extensive perivascular, highly CXCR3-positive T cell and macrophage infiltrates. Primary human skin cells displayed a comparable pattern of chemokine induction after stimulation with IFN-beta in vitro. IFN-beta may therefore trigger inflammatory skin reactions through local chemokine induction followed by rapid immune cell extravasation.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16126281     DOI： 10.1016/j.jneuroim.2005.07.011

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN： 0165-5728            Impact factor:   3.478


  16 in total

1.  Panniculitis and lipoatrophy after subcutaneous injection of interferon beta-1b in a patient with multiple sclerosis.

Authors:  S S O'Sullivan; E M Cronin; B J Sweeney; J F Bourke; J Fitzgibbon
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-06-16       Impact factor: 10.154

2.  Evaluation of serum levels of chemokines during interferon-β treatment in multiple sclerosis patients: a 1-year, observational cohort study.

Authors:  Elizabeth R Comini-Frota; Antonio L Teixeira; Janaína P A Angelo; Marcus V Andrade; Doralina G Brum; Damacio R Kaimen-Maciel; Norma T Foss; Eduardo A Donadi
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

3.  Inflammatory cytokine levels in chronic venous insufficiency ulcer tissue before and after compression therapy.

Authors:  Stephanie K Beidler; Christelle D Douillet; Daniel F Berndt; Blair A Keagy; Preston B Rich; William A Marston
Journal:  J Vasc Surg       Date:  2009-04       Impact factor: 4.268

4.  Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients' individual gene expression in peripheral blood.

Authors:  Michael Hecker; Christiane Hartmann; Ole Kandulski; Brigitte Katrin Paap; Dirk Koczan; Hans-Juergen Thiesen; Uwe Klaus Zettl
Journal:  Mol Neurobiol       Date:  2013-05-01       Impact factor: 5.590

5.  Microarray analysis identifies a set of CXCR3 and CCR2 ligand chemokines as early IFNbeta-responsive genes in peripheral blood lymphocytes in vitro: an implication for IFNbeta-related adverse effects in multiple sclerosis.

Authors:  Jun-ichi Satoh; Yusuke Nanri; Hiroko Tabunoki; Takashi Yamamura
Journal:  BMC Neurol       Date:  2006-05-19       Impact factor: 2.474

6.  Cutaneous Adverse Events Associated with Interferon-β Treatment of Multiple Sclerosis.

Authors:  Annette Kolb-Mäurer; Matthias Goebeler; Mathias Mäurer
Journal:  Int J Mol Sci       Date:  2015-07-02       Impact factor: 5.923

7.  Multiple cutaneous necrotic lesions associated with Interferon beta-1b injection for multiple sclerosis treatment: A case report and literature review.

Authors:  Gita Faghihi; Akram Basiri; Mohsen Pourazizi; Bahareh Abtahi-Naeini; Ali Saffaei
Journal:  J Res Pharm Pract       Date:  2015 Apr-Jun

8.  Soluble VCAM-1 impairs human brain endothelial barrier integrity via integrin α-4-transduced outside-in signalling.

Authors:  Axel Haarmann; Eva Nowak; Annika Deiß; Susanne van der Pol; Camelia-Maria Monoranu; Gijs Kooij; Nora Müller; Paul van der Valk; Guido Stoll; Helga E de Vries; Friederike Berberich-Siebelt; Mathias Buttmann
Journal:  Acta Neuropathol       Date:  2015-03-27       Impact factor: 17.088

9.  Type I interferon induces CX3CL1 (fractalkine) and CCL5 (RANTES) production in human pulmonary vascular endothelial cells.

Authors:  M Nakano; T Fujii; M Hashimoto; N Yukawa; H Yoshifuji; K Ohmura; A Nakaizumi; T Mimori
Journal:  Clin Exp Immunol       Date:  2012-10       Impact factor: 4.330

10.  Occurrence of Psoriatic Arthritis during Interferon Beta 1a Treatment for Multiple Sclerosis.

Authors:  Eric Toussirot; Matthieu Béreau; Marie Bossert; Imad Malkoun; Anne Lohse
Journal:  Case Rep Rheumatol       Date:  2014-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.